BeiGene (HKG:6160, SHA:688235) reported that its net loss for 2024 narrowed by 26.9% to $644.8 million from the $881.7 million loss a year earlier, according to a Thursday filing with the Hong Kong bourse.
Loss per share narrowed 27.7% to $0.47 from $0.65 loss per share a year ago.
Revenue rose 55.0% to $3.78 billion from $2.19 billion the previous year.
The company's shares were up 1% at the Hong Kong bourse while down less than 1% at the Shanghai bourse in recent trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.